BioSpace News Archive

Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today provided a clinical update on the impact of the COVID-19 pandemic on the status of NORSE 1 and NORSE 2, its ongoing registration clinical trials for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab.

BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported it has entered into an agreement for litigation financing which has been filed today with the Securities and Exchange Commission on Form 8-K. BioCardia, Inc. entered into a Litigation Funding Agreement with BSLF, L.L.C., an entity owned and controlled by Andrew Blank, a member of BioCardia’s

Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for solid and liquid tumors, today announced acceptance of its abstract titled Novel CoupledCAR® Technology for Treating Colorectal Cancer.

Inato, a marketplace that helps biopharmaceutical companies increase the pool of available patients engaged in clinical trials, today unveiled its anticovid platform, a comprehensive, central repository for all existing clinical trials for SARS-CoV 2 (the virus responsible for COVID-19).

Nunzia Pharmaceutical Launches its Breakthrough NUNZIA Nutraceutical and Pharma Treatment for Autism Spectrum and Other Anxiety Disorders

Parata Systems launched the Pharmacy Employee Relief Fund with an initial commitment of $100,000.

DiNovA Medtech, the leading medical devices incubator in China (“DiNovA”, or the “Company”), is pleased to announce Vivek Y. Reddy, MD to join as Chief Medical Advisor and Cofounder of portfolio company Nuomao Medtech (“Nuomao”) to lead cardiac arrhythmia related innovations.

GNS Healthcare is pleased to announce that Dr. Earl Steinberg, a nationally recognized expert in population health management, data analytics, and clinical informatics, has joined the company’s leadership team as a consultant to advance the company’s health plan offerings and drive clinical analytics efforts across GNS, particularly within biopharma market-access and value-based drug collaborations between biopharma and payers..

Surveillance Data Demonstrates Nationwide Prevalence of Antibiotic Resistant Bacteria Common in Eye Infections

Eko today announced the appointment of Adam Saltman, M.D., Ph.D., to the position of Chief Medical Officer (CMO).